Coronado Biosciences' CNDO-201 misses endpoints in Crohn's disease trial

Coronado Biosciences' (CNDO) TSO did not meet its primary endpoint in a Phase 2 Crohn's disease trial.

TRUST-1's primary endpoint was a 100-point decrease in CDAI and its secondary endpoint was remission (CDAI <150 points). Neither endpoint was met in patients with moderate-to-severe Crohn's disease.

The company says "the lack of overall response was driven by higher-than-expected placebo response rate in patients with CDAI < 290" and although CEO Harlan Weisman is "disappointed with the topline results," he says the company is "encouraged to see TSO's effect in patients with CDAI > 290."

Results from a second interim analysis of a second Phase 2 study are expected in Q4. (PR)

The shares fell 13% Friday.

Update 9:02: Coming off a halt, CNDO is down 68%.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs